


Abergel A, Hezode C, Asselah T. A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER. The International Liver Congress. Paris, France; 2018.


Bari K, Luckett K, Kaiser T. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver


Boerekamps A, Vanwolleghem T, Van Der Valk M. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). J Hepatol. 2019;70(3):554-557.


Coyle C, Moorman AC, Bartholomew T. The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA. Hepatology. 2019;.


who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sex Transm Infect. 2017;93(8):590-598.


Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV [Internet]. Department of Health and Human Services; 2017 [cited Accessed June 13, 2019].


German P, Pang P, West S, Han LL, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 19-21; Washington DC. 2014;.


Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, et al. Reinfection with hepatitis C virus following sustained


Henderson DK, Dembry L, Fishman NO, Grady C, Lundstrom T, Palmore TN, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect


Jiang Y, Nwankwo C. Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug in...


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/o/ without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/o without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-86.


Lawitz E, Landis C, Maliakkal B. Safety and efficacy of treatment with once daily ledipasvir/sofoobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment. The Liver Meeting. Boston, MA; 2017.


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR.


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. In EASL International Liver Meeting, April. 2017.

genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology.
2015;[Ahead of print].

Reddy KR, Pol S, Thuluvath PJ. Long-term follow-up of clinical trial patients treated for chronic HCV infection with

Reese PP, Abt PL, Blumberg EA. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected

Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation


Reilley B, Leston J, Redd JT, Geiger R. Lack of Access to Treatment as a Barrier to HCV Screening: A Facility-Based
Assessment in the Indian Health Service. J Public Health Manag Pract. 2013;.


virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany

Rich JD, Allen SA, Williams BA. Responding to Hepatitis C through the Criminal Justice System. New England Journal of


Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK- 8742) in
patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet
HIV. 2015;2(8):e319-327.

Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study [Abstract LBP-522]. In The International Liver Congress. EASL [Internet]. 2017. http://dx.doi.org/10.1016/S0168-8278(17)30467-1


Information sheet on naltrexone therapy [Internet]. Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Internal Medicine. 2015;175(9):1559-1560.


U.S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.


Walley AY, Xuan Z, Hackman HH. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346.


Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane EJ, Nelson DR, et al. Patient-reported outcomes in chronic


